Literature DB >> 8662966

Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo.

P C Rensen1, T J van Berkel.   

Abstract

Apolipoprotein E (apoE) is an important determinant for the liver uptake of triglyceride-rich lipoproteins and emulsions by the remnant receptor. In the current study, we assessed an additional role of apoE as modulator of the metabolism of triglyceride-rich lipoproteins in vitro and in vivo. Glycerol tri[3H]oleate [14C]cholesteryl oleate double-labeled triglyceride-rich emulsions were injected into fasted rats. The serum half-life of glycerol tri[3H]oleate was 3-fold faster (5.4 min) than that of [14C]cholesteryl oleate (16.7 min), confirming lipoprotein lipase (LPL)-mediated processing. To establish a specific effect of apoE on emulsion lipolysis rather than liver uptake, rats were functionally hepatectomized, and hypo(apo)lipoproteinemia was induced by 17alpha-ethinyl estradiol treatment. An apoE concentration-dependent inhibition of emulsion-triglyceride hydrolysis was observed, reaching a 14.8-fold increased half-life of glycerol tri[3H]oleate as compared with that in the absence of exogenous apoE. The mechanism and specificity of the effect of apoE on emulsion lipolysis by purified LPL was assessed in vitro. Addition of apoE to glycerol tri[3H]oleate-labeled emulsions led to a concentration-dependent inhibition of [3H]oleate release (9.5% residual LPL activity at 60 microg/ml apoE), while apoA-I was ineffective. The inhibitory effect of apoE was not abolished by reductive methylation of lysine residues, whereas selective modification of arginine residues by 1,2-cyclohexadione completely cancelled the inhibitory effect of apoE. It is concluded that apoE can specifically inhibit the LPL-mediated hydrolysis of emulsion triglycerides both in vitro and in vivo, and that arginine residues in apoE are essential for this effect. We suggest that in addition to its role in receptor recognition, apoE also modulates the LPL-mediated processing of triglyceride-rich lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8662966     DOI: 10.1074/jbc.271.25.14791

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Life is complicated: so is apoCIII.

Authors:  Gissette Reyes-Soffer; Henry N Ginsberg
Journal:  J Lipid Res       Date:  2019-06-25       Impact factor: 5.922

Review 2.  Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases.

Authors:  Werner J Geldenhuys; Li Lin; Altaf S Darvesh; Prabodh Sadana
Journal:  Drug Discov Today       Date:  2016-10-19       Impact factor: 7.851

3.  Molecular mechanisms responsible for the differential effects of apoE3 and apoE4 on plasma lipoprotein-cholesterol levels.

Authors:  Hui Li; Padmaja Dhanasekaran; Eric T Alexander; Daniel J Rader; Michael C Phillips; Sissel Lund-Katz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-14       Impact factor: 8.311

4.  Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density lipoproteins in plasma.

Authors:  J Fan; Z S Ji; Y Huang; H de Silva; D Sanan; R W Mahley; T L Innerarity; J M Taylor
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

5.  Molecular etiology of a dominant form of type III hyperlipoproteinemia caused by R142C substitution in apoE4.

Authors:  Alexander M Vezeridis; Konstantinos Drosatos; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2010-09-22       Impact factor: 5.922

6.  Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.

Authors:  T Ebara; R Ramakrishnan; G Steiner; N S Shachter
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

7.  apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL.

Authors:  Panagiotis Fotakis; Alexander Vezeridis; Ioannis Dafnis; Angeliki Chroni; Dimitris Kardassis; Vassilis I Zannis
Journal:  J Lipid Res       Date:  2014-04-28       Impact factor: 5.922

8.  Biophysical properties of apolipoprotein E4 variants: implications in molecular mechanisms of correction of hypertriglyceridemia.

Authors:  Irina N Gorshkova; Kyriakos E Kypreos; Donald L Gantz; Vassilis I Zannis; David Atkinson
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

Review 9.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

10.  Effect of dietary cholesterol oxidation products on the plasma clearance of chylomicrons in the rat.

Authors:  D F Vine; K D Croft; L J Beilin; J C L Mamo
Journal:  Lipids       Date:  2002-05       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.